Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

FDA approved Ionis Pharmaceuticals' drug Tryngolza, led by CEO Brett P. Monia.

4 reports, 4 independent Updated Sep 3
Gone quiet Reached 3 outlets in its first 24 hours
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

FDA approved Ionis Pharmaceuticals' drug Tryngolza, led by CEO Brett P. Monia.

Who's involved

What this event is mainly about
FDA

How it developed

Newest first. Tap a step to see who reported it.
  1. Ionis Pharmaceuticals received FDA approval for its drug Tryngolza.1 source
  2. Market success reported for Tryngolza following FDA approval.1 source

Keep exploring

Part of

A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

Also in this story

All 83 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • timesargus.com
  • BenzingaIonis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CO
  • GuruFocus.comIonis Pharmaceuticals Inc (IONS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ... Revenue: $452 million for Q2 2025, a two-fold increase year-over-year; $584 million for the first si
  • Business WireIonis reports second quarter 2025 financial results and highlights progress on key programs - TRYNGOLZATM delivers $19 million in net product sales in the second quarter 2025 - - Donidalorsen approva